|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US7807135||LIFE MOLECULAR||Stilbene derivatives and their use for binding and imaging amyloid plaques|| |
(5 years from now)
Neuraceq is owned by Life Molecular.
Neuraceq contains Florbetaben F-18.
Neuraceq has a total of 1 drug patent out of which 0 drug patents have expired.
Neuraceq was authorised for market use on 19 March, 2014.
Neuraceq is available in solution;intravenous dosage forms.
Neuraceq can be used as neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment.
The generics of Neuraceq are possible to be released after 18 March, 2029.
Market Authorisation Date: 19 March, 2014
Treatment: Neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic